4
Changes in Ownership
PHIBRO ANIMAL HEALTH CORP Filed Acc 0001104659-26-012073
President and CEO sold 110,842 shares at an average $48.38 ($5,362,103)
- President and CEO acquired 185,000 shares (conversion)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
BENDHEIM JACK · President and CEO
Table I: Non-derivative
7 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-02-05 | Conversion : show line 1 in the form 10b5-1 | +185,000 | 233,800 | I | ||
| 2026-02-05 | Sale : show line 2 in the form 10b5-1 | −409 | $44.47 | $18,188 | 233,391 | I |
| 2026-02-05 | Sale : show line 3 in the form 10b5-1 | −3,640 | $45.42 | $165,344 | 229,751 | I |
| 2026-02-05 | Sale : show line 4 in the form 10b5-1 | −3,171 | $46.68 | $148,027 | 226,580 | I |
| 2026-02-05 | Sale : show line 5 in the form 10b5-1 | −38,209 | $47.91 | $1,830,421 | 188,371 | I |
| 2026-02-05 | Sale : show line 6 in the form 10b5-1 | −46,275 | $48.65 | $2,251,418 | 142,096 | I |
| 2026-02-05 | Sale : show line 7 in the form 10b5-1 | −19,138 | $49.57 | $948,705 | 122,958 | I |
| Open-market sales · 110,842 sh · avg $48.38 · $5,362,103 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-02-05 | Conversion : show line 8 in the form 10b5-1 Class B Common Stock | −185,000 | 19,696,034 | I |
Loading xslF345X05/tm265586-1_4seq1.xml…